<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">14080</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title xml:lang="en">EFFECT OF THROMBODEFENSINS ON THE COURSE OF CHRONIC STAPHYLOCOCCI DERMATITIS ON IN VIVO MODEL</article-title><trans-title-group xml:lang="ru"><trans-title>ВЛИЯНИЕ ТРОМБОДЕФЕНСИНОВ НА ТЕЧЕНИЕ ХРОНИЧЕСКОГО СТАФИЛОКОККОВОГО ДЕРМАТИТА НА МОДЕЛИ IN VIVO</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ivanov</surname><given-names>Yu. B</given-names></name><name xml:lang="ru"><surname>Иванов</surname><given-names>Ю. Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gritsenko</surname><given-names>V. A</given-names></name><name xml:lang="ru"><surname>Гриценко</surname><given-names>В. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Miroshnikov</surname><given-names>C. A</given-names></name><name xml:lang="ru"><surname>Мирошников</surname><given-names>С. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Cellular and Intracellular Symbiosis, Orenburg, Russia</institution></aff><aff><institution xml:lang="ru">Институт клеточного и внутриклеточного симбиоза, Оренбург</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">All-Russian Research Institute of Meat Cattle-Breeding, Orenburg, Russia</institution></aff><aff><institution xml:lang="ru">Всероссийский НИИ мясного скотоводства, Оренбург</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2014-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2014</year></pub-date><volume>91</volume><issue>6</issue><issue-title xml:lang="en">NO6 (2014)</issue-title><issue-title xml:lang="ru">№6 (2014)</issue-title><fpage>104</fpage><lpage>108</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2014, Ivanov Y.B., Gritsenko V.A., Miroshnikov C.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2014, Иванов Ю.Б., Гриценко В.А., Мирошников С.А.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="en">Ivanov Y.B., Gritsenko V.A., Miroshnikov C.A.</copyright-holder><copyright-holder xml:lang="ru">Иванов Ю.Б., Гриценко В.А., Мирошников С.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/14080">https://microbiol.crie.ru/jour/article/view/14080</self-uri><abstract xml:lang="en"><p>Aim. Evaluate therapeutic effect of thrombodefensins (TD) on the course of chronic staphylococci dermatitis (CSD) in mice. Materials and methods. TD was obtained from human thrombocytes. 24 CBRB-Rb(8.17)1Iem line female mice were used in the experiment, that were divided into 2 equal groups. Staphylococcus aureus strain producing exfoliative exotoxin was isolated from withers of each mouse with signs of affection. Mice of the experiment group subcutaneously, around the locus of affection, received for 4 weeks daily a composition in the volume of 0.2 ml, that contains 1 g of dry lyophilized TD diluted in 10 ml of 0.9% NaCl (final concentration of the preparation - 15 ^g/ml). Control group animals similarly received 0.9% solution of NaCl without TD. Area and degree of the affected zone on the back was evaluated in all the mice. Statistical significance of differences in the values of parameters was determined by t-criteria. Results. At the start of the experiment the average area of the affected zone in mice of both groups was 167+17 mm 2. From day 8 to 23 the expansion of the affection zone was observed, however in the experiment group of mice these negative tendencies were less pronounced. At the end of the experiment on day 50 the area of affection was significantly smaller (2.3 times) in the experiment group of mice compared with the control (p&lt;0.05). Conclusion. The anti-staphylococci effect of TD, demonstrated in the study, opens perspective of their clinical use in CSD therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Оценить терапевтический эффект тромбодефенсинов (ТД) на течение хронического стафилококкового дерматита (ХСД) у мышей. Материалы и методы. ТД получали из тромбоцитов человека. В эксперименте использовали 24 самок мышей линии CBRB-Rb(8.17)1Iem, которые были разделены на две равные группы. С холки каждой мыши с признаками поражения был выделен штамм Staphylococcus aureus, продуцирующий эксфолиативный экзотоксин. В течение 4 недель ежедневно мышам опытной группы подкожно вокруг очага поражения в объеме 0,2 мл вводили композицию, состоящую из 1 грамма сухого лиофилизированного ТД, разведенного в 10 мл 0,9% раствора NaCl (конечная концентрация препарата - 15мкг/мл). Животным контрольной группы аналогично вводили 0,9% раствор NaCl без ТД. У всех мышей оценивали площадь и степень пораженного участка спины. Статистическую значимость различий в значениях параметров определяли с помощью t-критерия. Результаты. В начале эксперимента средняя площадь пораженного участка у мышей обеих групп составляла 167+17 мм 2. С 8 по 23 день наблюдали расширение площади поражения, однако у мышей опытной группы эти негативные тенденции были менее выражены. По окончании эксперимента на 50 день у мышей опытной группы площадь поражения была достоверно меньше (в 2,3 раза), чем в контроле (p&lt;0,05). Заключение. Показанный в работе антистафилококковый эффект ТД открывает перспективы их клинического использования в лечении ХСД.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic staphylococci dermatitis</kwd><kwd>mouse model</kwd><kwd>thrombodefensins</kwd><kwd>therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хронический стафилококковый дерматит</kwd><kwd>мышиная модель</kwd><kwd>тромбодефенсины</kwd><kwd>лечение</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Afshar M., Gallo R.L. Innate immune defense of the skin. Vet. Dermatol. 2013, 24(1):32-8.e8-9. doi: 10.1111/j.1365-3164.2012.01082.x.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Baker B.S. The role of microorganisms in atopic dermatitis. Clin. Exp. Immunol. 2006, 144: 1-9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bradshaw J. Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs. 2003, 17 (4): 233-240.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Brook I. Secondary bacterial infections complicating skin lesions. J. Med. Microbiol. 2002, 51: 808812.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ivanov I.B. In vitro resistance to human platelet microbicidal protein among urethral staphylococcal and enterococcal isolates with its correlation with prostatitis. Indian J. Med. Microbiol. 2005, 23 (4): 253-255.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ivanov I.B., Gritsenko VA. Comparative activities of cattle and swine platelet microbicidal proteins. Probiotics Antimicrob. Prot. 2009, 1 (2): 148-151.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Iwatsuki K., Yamasaki O., Morizane S. et al. Staphylococcal cutaneous infections: invasion, evasion and aggression. J. Dermatol. Sci. 2006, 42:203-214.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Jenssen H., Hamill P., Hancock R.E.W Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19: 491-511.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kupferwasser L.I., Skurray R.A., Brown M.H. et al. Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the qacA locus. Antimicrob. Agents Chemother. 1999, 43: 2395-2399.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lin Y.T., Wang C.T., Chiang B.L. Role ofbacterial pathogens in atopic dermatitis. Clin. Rev. Allergy Immunol. 2007, 33: 167-177.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Moiseeva E.V Original approaches to test anti-breast cancer drugs in a novel set of mouse models. Ph. D. Thesis, Utrecht University, Netherlands, 2005.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Noguchi N., Nakaminami H., Nishijima S. et al. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J. Clin. Microbiol. 2006, 44: 2119-2125.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Novick R.P., Geisinger E. Quorum sensing in staphylococci. Annu. Rev. Genet. 2008, 42: 541564.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Schroder J.-M., Harder J. Human beta-defensin-2. Int. J. Biochem. Cell. Biol. 1999, 31: 645651.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Vasilchenko A.S., Nikiyan H.N., Deryabin D.G. Atomic force microscopy study of magainin 2 versus human platelet extract action on Escherichia coli and Bacillus cereus. J. Biol. Res. 2013, 19: 3-9.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Yeaman M.R. Platelets in defense against bacterial pathogens. Cell. Mol. Life Sci. 2010, 67: 525544.</mixed-citation></ref></ref-list></back></article>
